In a randomized double-blind controlied trial of the value of intermittent topical idoxuridine in treating herpes zoster in 118 patients idoxuridine 5% in 100% dimethyl sulphoxide (DMSO), applied four-hourly for four days, significantly shortened the vesicular phase, healing time, and duration of pain; idoxuridine 25% applied two-hourly produced no greater benefit. The only side effects were transient tender erythema in three patients and "urticarial" oedema in two patients with dermographia.
Introduction
Idoxuridine was first shown to be active against varicellazoster virus in 1964 (Rapp and Vanderslice, 1964) . Subsequently Juel-Jensen et al. (1970) confirmed its clinical value of idoxuridine in a double-blind controlled trial showing that 5% idoxuridine in 100% dimethyl sulphoxide (DMSO)-a powerful solvenrt-shortened the healing time and also the duration of postherpetic pain. In view of this and also of the considerable, often protraoted, morbidity of zos;ter it seems surprising that idoxuridine has not ibeen prescribed more often. This has largely been due to controversy over the optimum concentration, frequency, and duration of idoxuridine application; its high cost, which is directly related to the concentration; and fear of toxicity from absorption in view of the toxicity of idoxuridine when given systemically (Silk and Roome, 1970; Juel-Jensen and MacCallum, 1972) . Less than 5% idoxuridine is of little clinical benefit in zoster, and there are no reported double-blind controlled trials to show unequivocally whether the optimum concentration should be greater for rouie clinical practice.
This double-blind controlled trial was carried out to assess further the efficacy of intermittent topical treatment with 5% idoxuridine in 100% DMSO (using 100% DMSO as control) and the toxicity of the treatment. Seven-teen patients complained of a garlic-like taste due to the therapy but they all completed the treatment. Three patients developed tender erythema in the treated area, two on ithe third, and one on the fourth day of -treatment; two had applied 100% DMSO every two hours and one 25% idoxuridine in 100% DMSO every two hours. The tender erythema renitted within hours of the end of treatment. Two patients with dermographia developed prominent localized areas of weals after the first, second, and third applications. Subsequent treatment was associated only with small, sparse, urticaria-like lesions.
Patients and Methods

General
Closed-patch testing was done on five normal subjects with (a) 5% idoxuridine in white paraffin, (b) 5% idoxuridine in 100% DMSO, (c) 100% DMSO, and (d) 10% DMSO in normal saline. All the results of tests in groups (b) RODNEY DAWBER, M.B., M.R.C.P., Consultant Dermatologist within 24 hours of removing the patch. No abnormalities of haemoglobin, W.B.C., platelet count, liver function, or blood urea were found during 'the course of the treatment.
Discussion
The results showed that intermittently applied 5 % idoxuridine in 100% DMSO had a considerable effect on zoster (equal to that of 25% idoxuridine), both in shortening the healing time and in reducing the duration of zoster neuralgia. These results broadly agree with those of others Juel-Jensen et al., 1970) . Juel-Jensen and MacCallum (1972) further suggested, however, that 40% idoxuridine in 100% DMSO, applied continuously on a dressing, gives even greater benefit. In view of the great expense of continuous application-up to £60 per patient Juel-Jensen, 1973)-the good results from intermittent 5% idoxuridine application as described here, and the failure of 25 % idoxuridine to give any greater benefit 5 % idoxuridine in 100% DMSO applied four-hourly is probably satisfactory for routine use. Idoxunidine 40% in 100% DMSO should be used only in the treatment of severe cases, under hospital supervision.
Systemic idoxuridine is potentially very toxic, particularly to the bone marrow, and should therefore be reserved for lifethreatening conditions such as herpes simplex encephalitis. No systemic abnormalities have yet been described after therapy with topical idoxuridine in DMSO. None of our 118 patients developed any overt signs of haematological, hepatic, or renal toxicity; the design of (the trial did leave open the possibility of transient impairment of these organs during the early stages of treatment. Nevertheless, the absence of symptoms and signs of toxicity during ithis period, the subsequent normal results of investigations, and the absence of reported side effects all show the application to be safe. Since idoxuridine interferes with DNA synthesis and cell division it is on no accoun,tto be recommended for pregnant women, and it cannot be recommended for children until results of its use in them have been studied.
The patch tests showed that DMSO is a primary irritant, which probably explains ithe reports of maceration of skin (Juel-Jensen and MacCallum, 1972) , and even full-thickness skin loss (Dawber, 1973) , after treatment with high concentrations of DMSO, which were applied very of-ten for many days. Because treatment was intermittent only slight tender erythma occurred in: a few patients in this study.
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